Heterocyclic compound as protein degradation agent, pharmaceutical composition containing heterocyclic compound and application of heterocyclic compound
Designing selective AR degradants through PROTAC technology, using the ubiquitin-proteasome system to degrade androgen receptors, solving the problem of difficult and drug resistance to existing drugs for the treatment of metastatic castration resistance to prostate cancer, and achieving AR Effective blockade of signaling extends the therapeutic effect.
Patent Information
- Application Number
- CN202411018753.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2019-09-29
- Filing Date
- 2020-09-24
- Publication Date
- 2024-11-12
AI Technical Summary
The existing drug effect of metastatic castration-resistant prostate cancer is difficult to maintain, and androgen receptor mutations lead to drug resistance, lack of effective selective androgen receptor degradants (SARDs) to block androgen receptor signaling .
The protein degradation targeted chimera (PROTAC) technology is used to design selective androgen receptor (AR) degradation agents, degradation of AR through the ubiquitin-proteasome system, and the target protein and proteasome system are used to interact with each other. The ternary complex is formed to achieve AR degradation.
By selectively degrading androgen receptors, blocking their signaling process, prolonging therapeutic effects, and avoiding drug resistance, it provides new options for treating prostate cancer.
Smart Images

Figure CN118930604A_ABST
Abstract
Description
[0001] This application is a divisional application of Chinese patent application No. 202011017293.6, filed on September 24, 2020, entitled “Heterocyclic compounds as protein degraders, preparation methods and medical applications thereof”. Technical Field
[0002] The present invention relates to a compound represented by formula (I) and a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the compound or the salt thereof, and application of the compound as an androgen receptor (AR) degradation agent. Background Art
[0003] Prostate cancer (PCa) is one of the most common cancers. Prostate cancer has no obvious symptoms in the early stages, so when patients are diagnosed, they are usually in the late stages, with symptoms such as frequent urination, dysuria, hematuria, and pain during urination, and may metastasize to other parts of the body.
[0004] Prostate cancer is an androgen-dependent tumor. Androgens can stimulate the growth of prostate cancer cells and the progression of the disease, so endocrine therapy, such as androgen deprivation therapy (ADT) (surgical castration / medical castration), is one of the conventional treatments. ADT therapy has a significant effect in the early stages of treatment, but with the use of drugs and the progression of the disease, the androgen receptor (AR) will mutate, and the mutated AR will be more sensitive to low levels of androgens, causing the disease to progress to castration-resistant prostate cancer (CRPC). Studies have shown that almost all patients with advanced prostate cancer will eventually progress to CRPC after receiving endocrine therapy; in addition, up to 30% of prostate cancer patients will transform into metastatic castration-resistant prostate cancer (mCRPC) within 10 years of initial treatment. At present, patients clinically diagnosed with early-stage localized prostate cancer are usually cured, but patients diagnosed with asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer (mCRPC) have no clinical cure options.
[0005] Currently approved oral drugs for the treatment of metastatic castration-resistant prostate cancer mainly include abiraterone and enzalutamide. Among them, abiraterone is a new type of androgen biosynthesis inhibitor, which can block the synthesis of androgens in the testis, adrenal glands or tumor cells; enzalutamide is an androgen receptor antagonist that can competitively inhibit the binding of androgens to receptors. In addition, after enzalutamide binds to AR, it can also further inhibit the nuclear transport of AR, thereby blocking the interaction between AR and DNA.
[0006] ADT therapy is difficult to maintain long-term efficacy because CRPC still relies on the AR signaling axis to maintain growth. AR mutations reduce the activity of traditional small molecule antagonists acting on AR, and even convert them into AR agonists, resulting in drug resistance in clinical practice. Selective androgen receptor degraders (SARDs) can degrade androgen receptors, thereby completely blocking the androgen receptor signaling process, which will bring more benefits.
[0007] The present invention mainly relies on the protein degradation targeted chimera (PROTAC) technology to obtain a class of selective AR degraders (SARD). PROTAC technology mainly relies on the ubiquitin-proteasome system in the cell. This system is the "cleaner" in the cell, and the main function of the ubiquitination system is to ubiquitinate denatured, mutated or harmful proteins in the cell. Ubiquitinated proteins are degraded by the proteasome system inside the cell. The design idea of PROTAC is that one end of the molecule is a target protein (such as AR) interaction fragment, and the other end is a ubiquitin-proteasome (E3 ligase part) interaction fragment, and the two ends are connected to form a chimeric molecule through an intermediate connection (Linker). PROTAC interacts with the target protein (AR) and the proteasome system at the same time, so that the proteasome and the target protein (such as AR) are close to each other in space, thereby causing AR to be ubiquitinated and degraded. Small molecule PROTAC technology was reported in 2008. At present, only Arvinas's small molecule drug ARV-110 (currently unknown structure) based on AR degradation is in the clinical phase I research and development stage.
[0008]
[0009] At present, PROTAC technology belongs to the cutting-edge field. The detailed mechanism of action of this type of molecule is still unclear, but there is evidence that it is far more complex than traditional small molecule drugs. Preliminary studies believe that PROTAC exerts its protein degradation effect by forming a ternary protein complex of "target protein-PROTAC-E3 ligase", which involves the problem of three-body binding kinetics. The formation of the ternary complex competes with the formation of the two binary complexes of "target protein-PROTAC" and "PROTAC-E3 ligase", so the strength of the PROTAC effect is not necessarily linearly related to its concentration in the cell (such as the presence of a hook effect). In addition, studies have shown that the stability of the "target protein-PROTAC-E3 ligase" ternary complex is the key to the protein degradation effect. This means that the affinity of PROTAC itself to the target protein (such as AR) has nothing to do with the activity of PROTAC, and the fine-tuning of the PROTAC Linker part may affect the protein-protein interaction of the target protein-E3 ligase.
[0010] In summary, the molecular design of PROTAC is completely different from the traditional small molecule design, and there is no certain rule to follow. This also means that common drug modification strategies (such as equivalent replacement of effective fragments, etc.) may not be applicable in the design of such molecules. For example, Alessio Ciulli et al. published an article in 2018 showing that for the degradation of certain target proteins, some weakly active target protein fragments were used, and the derived PROTAC molecules had stronger protein degradation activity (J.Med.Chem.2018,61,504-513).
[0011] Currently, there is still a need in the art to develop PROTAC molecules with novel structures for AR degradation. Summary of the invention
[0012] The present invention provides a compound represented by formula (I), an optical isomer thereof or a pharmaceutically acceptable salt thereof,
[0013]
[0014] in,
[0015] Ring A is selected from 3-9 membered heterocycloalkyl and C 3-9 Cycloalkyl;
[0016] R1 is selected from OH, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, -C(=O)-C 1-6 Alkyl, -NHC(=O)-C 1-6 Alkyl and -C(=O)NH-C 1-6 Alkyl, wherein the C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, -C(=O)-C 1-6 Alkyl, -NHC(=O)-C 1-6 Alkyl or -C(=O)NH-C 1-6 The alkyl group is optionally substituted with 1, 2 or 3 R';
[0017] R2 is selected from H, halogen, OH, NH2, CN, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino and -C(=O)-C 1-6 Alkyl, wherein the C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino or -C(=O)-C 1-6 The alkyl group is optionally substituted with 1, 2 or 3 R';
[0018] R6 and R7 are independently selected from H, halogen and C 1-6 Alkyl, wherein the C 1-6 The alkyl group is optionally substituted with 1, 2 or 3 R';
[0019] Alternatively, R6 and R7 are linked together to form a 3-12 membered heterocycloalkyl or C 3-12 Cycloalkyl, wherein the 3-12 membered heterocycloalkyl or C 3-12 Cycloalkyl is optionally substituted with 1, 2 or 3 Ra;
[0020] Alternatively, R7 and ring B are connected together to form a 3-12 membered heterocycloalkyl, C 3-12 Cycloalkyl, C 6-10 aryl or 5-12 membered heteroaryl, wherein the 3-12 membered heterocycloalkyl, C 3-12 Cycloalkyl, C 6-10 Aryl or 5-12 membered heteroaryl is optionally substituted with 1, 2 or 3 Ra;
[0021] Ra are independently selected from H, halogen and C 1-6 Alkyl, wherein the C 1-6 The alkyl group is optionally substituted with 1, 2 or 3 R';
[0022] Ring B is selected from C 6-10 Aryl and 5-10 membered heteroaryl;
[0023] R3 is selected from H, halogen, OH, NH2, CN, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, phenyl, naphthyl and 5-10 membered heteroaryl, wherein the C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, phenyl, naphthyl or 5-10 membered heteroaryl is optionally substituted with 1, 2 or 3 R';
[0024] Ring C is selected from C 6-10 Aryl and 5-10 membered heteroaryl, wherein the C 6-10 Aryl or 5-10 membered heteroaryl is optionally substituted with 1, 2 or 3 R';
[0025] R4 and R5 are independently selected from H, NO2, halogen, NH2, CN, C 1-6 Alkyl and C 1-6 Alkoxy, wherein the C 1-6 Alkyl or C 1-6 Alkoxy is optionally substituted with 1, 2 or 3 halogens, OH, NH2;
[0026] L1, L2, L3, L4 are independently selected from a single bond, O, S, NH, C(=O), S(=O), S(=O)2, C 1-6 Alkyl, -C 1-6 Alkyl-O-, C 2-3 Alkenyl, C 2-3 Alkynyl, C 3-10 Cycloalkyl, 3-10 membered heterocycloalkyl, phenyl and 5-9 membered heteroaryl, wherein the C 1-6 Alkyl, -C 1-6 Alkyl-O-, C 2-3 Alkenyl, C 2-3 Alkynyl, C 3-10 Cycloalkyl, 3-10 membered heterocycloalkyl, phenyl or 5-9 membered heteroaryl are optionally substituted with 1, 2 or 3 R L replace;
[0027] R L are independently selected from H, halogen, OH, NH2, CN, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 Alkyl-C(=O)-, C 1-6 Alkoxy, C 1-6 Alkylthio and C 1-6 Alkylamino, wherein the C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 Alkyl-C(=O)-, C 1-6 Alkoxy, C 1-6 Alkylthio or C 1-6 The alkylamino group is optionally substituted with 1, 2 or 3 R';
[0028] R' is independently selected from H, halogen, C 1-6 Alkyl, C 1-6 Alkoxy, OH, NH2, CH3, CH2F, CHF2 and CF3;
[0029] The above 3-9 membered heterocycloalkyl, 3-10 membered heterocycloalkyl, 3-12 membered heterocycloalkyl, 5-6 membered heteroaryl, 5-9 membered heteroaryl or 5-10 membered heteroaryl contains 1, 2 or 3 heteroatoms or heteroatom groups independently selected from O, NH, S, C(=O), C(=O)O, S(=O), S(=O)2 and N.
[0030] In another aspect of the present invention, the present invention also provides a compound represented by formula (I-A), an optical isomer thereof or a pharmaceutically acceptable salt thereof,
[0031]
[0032] in,
[0033] R1 is selected from OH, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, -C(=O)-C 1-6 Alkyl, -NHC(=O)-C 1-6 Alkyl and -C(=O)NH-C 1-6 Alkyl, wherein the C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, -C(=O)-C 1-6 Alkyl, -NHC(=O)-C 1-6 Alkyl or -C(=O)NH-C 1-6 The alkyl group is optionally substituted with 1, 2 or 3 R';
[0034] R2 is selected from H, halogen, OH, NH2, CN, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino and -C(=O)-C 1-6 Alkyl, wherein the C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino or -C(=O)-C 1-6 The alkyl group is optionally substituted with 1, 2 or 3 R';
[0035] n1 is 1 or 2;
[0036] n2 is 0, 1 or 2;
[0037] X1 is selected from O or N;
[0038] R6 and R7 are independently selected from H, halogen and C 1-6 Alkyl, wherein the C 1-6 The alkyl group is optionally substituted with 1, 2 or 3 R';
[0039] Alternatively, R6 and R7 are linked together to form a 3-12 membered heterocycloalkyl or C 3-12 Cycloalkyl, wherein the 3-12 membered heterocycloalkyl or C 3-12 Cycloalkyl is optionally substituted with 1, 2 or 3 Ra;
[0040] Alternatively, R7 and ring B are connected together to form a 3-12 membered heterocycloalkyl, C 3-12 Cycloalkyl, C 6-10 aryl or 5-12 membered heteroaryl, wherein the 3-12 membered heterocycloalkyl, C 3-12 Cycloalkyl, C 6-10Aryl or 5-12 membered heteroaryl is optionally substituted with 1, 2 or 3 Ra;
[0041] Ra are independently selected from H, halogen and C 1-6 Alkyl, wherein the C 1-6 The alkyl group is optionally substituted with 1, 2 or 3 R';
[0042] Ring B is selected from C 6-10 Aryl and 5-10 membered heteroaryl;
[0043] R3 is selected from H, halogen, OH, NH2, CN, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, phenyl, naphthyl and 5-10 membered heteroaryl, wherein the C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, phenyl, naphthyl or 5-10 membered heteroaryl is optionally substituted with 1, 2 or 3 R';
[0044] Ring C is selected from C 6-10 Aryl and 5-10 membered heteroaryl, wherein the C 6-10 Aryl or 5-10 membered heteroaryl is optionally substituted with 1, 2 or 3 R';
[0045] R4 and R5 are independently selected from H, NO2, halogen, NH2, CN, C 1-6 Alkyl and C 1-6 Alkoxy, wherein the C 1-6 Alkyl or C 1-6 Alkoxy is optionally substituted with 1, 2 or 3 halogens, OH, NH2;
[0046] L1, L2, L3, L4 are independently selected from a single bond, O, S, NH, C(=O), S(=O), S(=O)2, C 1-6 Alkyl, -C 1-6 Alkyl-O-, C 2-3 Alkenyl, C 2-3 Alkynyl, C 3-10 Cycloalkyl, 3-10 membered heterocycloalkyl, phenyl and 5-9 membered heteroaryl, wherein the C 1-6 Alkyl, -C 1-6 Alkyl-O-, C 2-3 Alkenyl, C 2-3 Alkynyl, C 3-10 Cycloalkyl, 3-10 membered heterocycloalkyl, phenyl or 5-9 membered heteroaryl are optionally substituted with 1, 2 or 3 R L replace;
[0047] R Lare independently selected from H, halogen, OH, NH2, CN, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 Alkyl-C(=O)-, C 1-6 Alkoxy, C 1-6 Alkylthio and C 1-6 Alkylamino, wherein the C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 Alkyl-C(=O)-, C 1-6 Alkoxy, C 1-6 Alkylthio or C 1-6 The alkylamino group is optionally substituted with 1, 2 or 3 R';
[0048] R' is independently selected from H, halogen, C 1-6 Alkyl, C 1-6 Alkoxy, OH, NH2, CH3, CH2F, CHF2 and CF3;
[0049] The above 3-9 membered heterocycloalkyl, 3-10 membered heterocycloalkyl, 3-12 membered heterocycloalkyl, 5-6 membered heteroaryl, 5-9 membered heteroaryl or 5-10 membered heteroaryl contains 1, 2 or 3 heteroatoms or heteroatom groups independently selected from O, NH, S, C(=O), C(=O)O, S(=O), S(=O)2 and N.
[0050] In another aspect of the present invention, the present invention also provides a compound represented by formula (I-B), an optical isomer thereof and a pharmaceutically acceptable salt thereof,
[0051]
[0052] in,
[0053] R1 is selected from OH, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, -C(=O)-C 1-6 Alkyl, -NHC(=O)-C 1-6 Alkyl and -C(=O)NH-C 1-6 Alkyl, wherein the C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, -C(=O)-C 1-6 Alkyl, -NHC(=O)-C 1-6 Alkyl or -C(=O)NH-C 1-6 The alkyl group is optionally substituted with 1, 2 or 3 R';
[0054] R2 is selected from H, halogen, OH, NH2, CN, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino and -C(=O)-C 1-6 Alkyl, wherein the C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino or -C(=O)-C 1-6 The alkyl group is optionally substituted with 1, 2 or 3 R';
[0055] n1 is 1 or 2;
[0056] n2 is 0, 1 or 2;
[0057] X1 is selected from O and N;
[0058] X2 is selected from N, CH and C(F);
[0059] R6 and R7 are independently selected from H, halogen and C 1-6 Alkyl, wherein the C 1-6 The alkyl group is optionally substituted with 1, 2 or 3 R';
[0060] Alternatively, R6 and R7 are linked together to form a 3-12 membered heterocycloalkyl or C 3-12 Cycloalkyl, wherein the 3-12 membered heterocycloalkyl or C 3-12 Cycloalkyl is optionally substituted with 1, 2 or 3 Ra;
[0061] Or, R7 and R 3a The connected benzene rings are connected together to form a 3-12 membered heterocycloalkyl, C 3-12 Cycloalkyl, C 6-10 aryl or 5-12 membered heteroaryl, wherein the 3-12 membered heterocycloalkyl, C 3-12 Cycloalkyl, C 6-10 Aryl or 5-12 membered heteroaryl is optionally substituted with 1, 2 or 3 Ra;
[0062] Ra are independently selected from H, halogen and C 1-6 Alkyl, wherein the C 1-6 The alkyl group is optionally substituted with 1, 2 or 3 R';
[0063] R 3a Selected from H, halogen, OH, NH2, CN, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, phenyl, naphthyl and 5-10 membered heteroaryl, wherein the C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6Alkylamino, phenyl, naphthyl or 5-10 membered heteroaryl is optionally substituted with 1, 2 or 3 R';
[0064] R4 and R5 are independently selected from H, NO2, halogen, NH2, CN, C 1-6 Alkyl and C 1-6 Alkoxy, wherein the C 1-6 Alkyl or C 1-6 Alkoxy is optionally substituted with 1, 2 or 3 halogens, OH, NH2;
[0065] L1, L2, L3, L4 are independently selected from a single bond, O, S, NH, C(=O), S(=O), S(=O)2, C 1-6 Alkyl, -C 1-6 Alkyl-O-, C 2-3 Alkenyl, C 2-3 Alkynyl, C 3-10 Cycloalkyl, 3-10 membered heterocycloalkyl, phenyl and 5-9 membered heteroaryl, wherein the C 1-6 Alkyl, -C 1-6 Alkyl-O-, C 2-3 Alkenyl, C 2-3 Alkynyl, C 3-10 Cycloalkyl, 3-10 membered heterocycloalkyl, phenyl or 5-9 membered heteroaryl are optionally substituted with 1, 2 or 3 R L replace;
[0066] R L are independently selected from H, halogen, OH, NH2, CN, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 Alkyl-C(=O)-, C 1-6 Alkoxy, C 1-6 Alkylthio and C 1-6 Alkylamino, wherein the C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Alkyl-C(=O)-, C 1-6 Alkylthio or C 1-6 The alkylamino group is optionally substituted with 1, 2 or 3 R';
[0067] R' is independently selected from H, halogen, C 1-6 Alkyl, C 1-6 Alkoxy, OH, NH2, CH3, CH2F, CHF2 and CF3;
[0068] The above 3-9 membered heterocycloalkyl, 3-10 membered heterocycloalkyl, 3-12 membered heterocycloalkyl, 5-6 membered heteroaryl, 5-9 membered heteroaryl or 5-10 membered heteroaryl contains 1, 2 or 3 heteroatoms or heteroatom groups independently selected from O, NH, S, C(=O), C(=O)O, S(=O), S(=O)2 and N.
[0069] In another aspect of the present invention, the present invention also provides a compound represented by formula (I-C), an optical isomer thereof and a pharmaceutically acceptable salt thereof,
[0070]
[0071] in,
[0072] R1 is selected from OH, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, -C(=O)-C 1-6 Alkyl, -NHC(=O)-C 1-6 Alkyl and -C(=O)NH-C 1-6 Alkyl, wherein the C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, -C(=O)-C 1-6 Alkyl, -NHC(=O)-C 1-6 Alkyl or -C(=O)NH-C 1-6 The alkyl group is optionally substituted with 1, 2 or 3 R';
[0073] R2 is selected from H, halogen, OH, NH2, CN, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino and -C(=O)-C 1-6 Alkyl, wherein the C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino or -C(=O)-C 1-6 The alkyl group is optionally substituted with 1, 2 or 3 R';
[0074] R6 and R7 are independently selected from H, halogen and C 1-6 Alkyl, wherein the C 1-6 The alkyl group is optionally substituted with 1, 2 or 3 R';
[0075] Alternatively, R6 and R7 are linked together to form a 3-12 membered heterocycloalkyl or C 3-12 Cycloalkyl, wherein the 3-12 membered heterocycloalkyl or C 3-12 Cycloalkyl is optionally substituted with 1, 2 or 3 Ra;
[0076] Ra are independently selected from H, halogen and C 1-6 Alkyl, wherein the C 1-6 The alkyl group is optionally substituted with 1, 2 or 3 R';
[0077] n1 is 1 or 2;
[0078] n2 is 0, 1 or 2;
[0079] X1 is selected from O or N;
[0080] X2 is selected from N, CH and C(F);
[0081] X3 is selected from CH2, NH, S and O;
[0082] X4 and X5 are each independently selected from CH or N;
[0083] R 3b Selected from H, halogen, OH, NH2, CN, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, phenyl, naphthyl and 5-10 membered heteroaryl, wherein the C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, phenyl, naphthyl or 5-10 membered heteroaryl is optionally substituted with 1, 2 or 3 R';
[0084] R4 and R5 are independently selected from H, NO2, halogen, NH2, CN, C 1-6 Alkyl and C 1-6 Alkoxy, wherein the C 1-6 Alkyl or C 1-6 Alkoxy is optionally substituted with 1, 2 or 3 halogens, OH, NH2;
[0085] L1, L2, L3, L4 are independently selected from a single bond, O, S, NH, C(=O), S(=O), S(=O)2, C 1-6 Alkyl, -C 1-6 Alkyl-O-, C 2-3 Alkenyl, C 2-3 Alkynyl, C 3-10 Cycloalkyl, 3-10 membered heterocycloalkyl, phenyl and 5-9 membered heteroaryl, wherein the C 1-6 Alkyl, -C 1-6 Alkyl-O-, C 2-3 Alkenyl, C 2-3 Alkynyl, C 3-10 Cycloalkyl, 3-10 membered heterocycloalkyl, phenyl or 5-9 membered heteroaryl are optionally substituted with 1, 2 or 3 R L replace;
[0086] R L are independently selected from H, halogen, OH, NH2, CN, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 Alkyl-C(=O)-, C 1-6 Alkoxy, C 1-6 Alkylthio and C 1-6 Alkylamino, wherein the C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 Alkyl-C(=O)-, C 1-6 Alkoxy, C 1-6 Alkylthio or C 1-6 The alkylamino group is optionally substituted with 1, 2 or 3 R';
[0087] R' is independently selected from H, halogen, C 1-6 Alkyl, OH, NH2, CH3, CH2F, CHF2 and CF3;
[0088] The above-mentioned 3-9 membered heterocycloalkyl, 3-10 membered heterocycloalkyl, 3-12 membered heterocycloalkyl, 5-6 membered heteroaryl, 5-9 membered heteroaryl or 5-10 membered heteroaryl contains 1, 2 or 3 heteroatoms or heteroatom groups independently selected from O, NH, S, C(=O), C(=O)O, S(=O), S(=O)2 and N.
[0089] In some technical embodiments of the present invention, ring A is selected from 3-6 membered heterocycloalkyl and C 3-6 The remaining variables are as defined herein.
[0090] In some technical embodiments of the present invention, ring A is selected from oxirane, oxetanyl, azetidinyl, tetrahydrofuranyl, tetrahydro-2H-pyranyl and piperidinyl, and the remaining variables are as defined in the present invention.
[0091] In some technical solutions of the present invention, ring A is selected from The remaining variables are as defined in the present invention.
[0092] In some technical solutions of the present invention, R2 is selected from H, halogen, OH, NH2, CN, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylamino and -C(=O)-C 1-3 Alkyl, the C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylamino or -C(=O)-C 1-3The alkyl group is optionally substituted with 1, 2 or 3 R's, and the remaining variables are as defined herein.
[0093] In some technical schemes of the present invention, R2 is selected from H, halogen, OH, NH2, CN, methyl, ethyl, n-propyl, isopropyl, methoxy and -C(=O)CH3, and the remaining variables are as defined in the present invention.
[0094] In some technical solutions of the present invention, R1 is selected from OH, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylamino, -C(=O)-C 1-3 Alkyl, -NHC(=O)-C 1-3 Alkyl and -C(=O)NH-C 1-3 Alkyl, the C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylamino, -C(=O)-C 1-3 Alkyl, -NHC(=O)-C 1-3 Alkyl or -C(=O)NH-C 1-3 The alkyl group is optionally substituted with 1, 2 or 3 R's, and the remaining variables are as defined herein.
[0095] In some technical solutions of the present invention, R1 is selected from OH, methyl, ethyl, n-propyl and isopropyl, and the remaining variables are as defined in the present invention.
[0096] In some technical solutions of the present invention, the structural unit Selected from The remaining variables are as defined in the present invention.
[0097] In some technical solutions of the present invention, the structural unit Selected from The remaining variables are as defined in the present invention.
[0098] In some technical solutions of the present invention, the structural unit Selected from The remaining variables are as defined in the present invention.
[0099] In some technical solutions of the present invention, the structural unit Selected from The remaining variables are as defined in the present invention.
[0100] In some technical embodiments of the present invention, ring B is selected from phenyl, naphthyl and 5-9 membered heteroaryl, and the remaining variables are as defined in the present invention.
[0101] In some technical embodiments of the present invention, ring B is selected from phenyl, naphthyl, benzothiazolyl, 1H-indazolyl and benzimidazolyl, and the remaining variables are as defined in the present invention.
[0102] In some technical solutions of the present invention, ring B is selected from phenyl, naphthyl, The remaining variables are as defined in the present invention.
[0103] In some technical solutions of the present invention, R3, R 3a , R 3b are independently selected from H, halogen, OH, NH2, CN, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylamino, phenyl, naphthyl and thienyl, the C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 The alkylamino, phenyl, naphthyl or thienyl group is optionally substituted with 1, 2 or 3 R's, and the remaining variables are as defined herein.
[0104] In some technical solutions of the present invention, R' is selected from H, halogen and C 1-3 Alkyl, OH, NH2, CH3, CH2F, CHF2 and CF3, and the remaining variables are as defined in the present invention.
[0105] In some technical solutions of the present invention, the structural unit Selected from The remaining variables are as defined in the present invention.
[0106] In some technical solutions of the present invention, the structural unit Selected from The remaining variables are as defined in the present invention.
[0107] In some technical solutions of the present invention, ring C is selected from phenyl and pyridyl, and the phenyl or pyridyl is optionally substituted by 1, 2 or 3 R's, and the remaining variables are as defined in the present invention.
[0108] In some technical solutions of the present invention, ring C is selected from The remaining variables are as defined in the present invention.
[0109] In some technical solutions of the present invention, the structural unit for The remaining variables are as defined in the present invention.
[0110] In some technical solutions of the present invention, the structural unit for The remaining variables are as defined in the present invention.
[0111] In some technical solutions of the present invention, the structural unit Selected from The remaining variables are as defined in the present invention.
[0112] In some technical solutions of the present invention, the structural unit Selected from The remaining variables are as defined in the present invention.
[0113] In some technical schemes of the present invention, R4 and R5 are independently selected from H, NO2, F, Cl, Br, I, NH2, CN, methyl, ethyl, n-propyl, isopropyl, methoxy and ethoxy, and the remaining variables are as defined in the present invention.
[0114] In some technical solutions of the present invention, L1, L2, L3, and L4 are independently selected from a single bond, O, S, NH, C(=O), S(=O), S(=O)2, C 1-3 Alkyl, -C 1-3 Alkyl-O-, C 2-3 Alkenyl, C 2-3 Alkynyl, C 3-6 Cycloalkyl, 5-6 membered heterocycloalkyl, phenyl and 5-6 membered heteroaryl, wherein the C 1-3 Alkyl, -C 1-3 Alkyl-O-, C 2-3 Alkenyl, C 2-3 Alkynyl, C 3-6 Cycloalkyl, 5-6 membered heterocycloalkyl, phenyl or 5-6 membered heteroaryl is optionally substituted by 1, 2 or 3 R L The remaining variables are as defined in the present invention.
[0115] In some technical solutions of the present invention, R L are independently selected from H, halogen, OH, NH2, CN, C 1-3 Alkyl, C 3-6 Cycloalkyl, C 1-3 Alkyl-C(=O)-, C 1-3 Alkoxy, C 1-3 Alkylthio and C 1-3 Alkylamino, wherein the C 1-3 Alkyl, C 3-6 Cycloalkyl, C 1-3 Alkyl-C(=O)-, C 1-3 Alkoxy, C 1-3 Alkylthio or C 1-3 The alkylamino group is optionally substituted with 1, 2 or 3 R's, and the remainder of the variables are as defined herein.
[0116] In some technical solutions of the present invention, R L are independently selected from H, methyl and -CH2OH, and the remaining variables are as defined herein.
[0117] In some technical solutions of the present invention, L1, L2, L3, and L4 are independently selected from a single bond, O, S, NH, C(=O), S(=O), S(=O)2, CH2,
[0118] The remaining variables are as defined in the present invention.
[0119] In some technical solutions of the present invention, the structural unit Selected from
[0120] The remaining variables are as defined in the present invention.
[0121] In some technical schemes of the present invention, R6 and R7 are connected together to form a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, oxetanyl, tetrahydrofuranyl, tetrahydrothienyl or tetrahydropyranyl, wherein the cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, oxetanyl, tetrahydrofuranyl, tetrahydrothienyl or tetrahydropyranyl is optionally substituted by 1, 2 or 3 Ra, and the remaining variables are as defined in the present invention.
[0122] In some technical schemes of the present invention, R7 is connected with ring B to form a furanyl, thienyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, piperidinyl, piperazinyl or oxahedral, wherein the furanyl, thienyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, piperidinyl, piperazinyl or oxahedral are optionally substituted with 1, 2 or 3 Ra, and the remaining variables are as defined in the present invention.
[0123] In some technical solutions of the present invention, R7 and R 3a The connected benzene rings are connected together to form a furanyl, thienyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, piperidinyl, piperazinyl or oxepanyl, wherein the furanyl, thienyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, piperidinyl, piperazinyl or oxepanyl is optionally substituted with 1, 2 or 3 Ra, and the remaining variables are as defined in the present invention.
[0124] In another aspect of the present invention, the present invention also provides the following compounds, their optical isomers and pharmaceutically acceptable salts, which are selected from
[0125]
[0126] In yet another aspect of the present invention, the present invention also provides a pharmaceutical composition. In some embodiments of the present invention, the pharmaceutical composition protects the aforementioned compound, its optical isomers and pharmaceutically acceptable salts thereof.
[0127] In some embodiments of the present invention, the above-mentioned pharmaceutical composition further comprises a pharmaceutical excipient.
[0128] In another aspect of the present invention, the present invention also provides the use of the aforementioned compound, its optical isomers and pharmaceutically acceptable salts thereof or the aforementioned pharmaceutical composition in the preparation of drugs for preventing and / or treating cancer, prostate cancer, and Kennedy's disease.
[0129] In some embodiments of the present invention, the above-mentioned cancer is selected from prostate cancer, breast cancer, ovarian cancer, cervical cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, hepatocellular carcinoma and renal cell carcinoma, bladder cancer, intestinal cancer, colon cancer, esophageal cancer, head cancer, kidney cancer, liver cancer, lung cancer, cervical cancer, testicular cancer, pancreatic cancer and gastric cancer; leukemia; benign and malignant lymphoma; malignant melanoma; myeloproliferative disease; sarcoma; thyroid cancer, astrocytoma, melanoma; carcinosarcoma, Hodgkin's disease, Wilman tumor or teratoma.
[0130] In some embodiments of the present invention, the above-mentioned benign and malignant lymphomas include Burkitt's lymphoma and non-Hodgkin's lymphoma.
[0131] In some embodiments of the present invention, the above-mentioned sarcoma includes Ewing sarcoma, angiosarcoma, Kaposi's sarcoma, liposarcoma, myosarcoma, peripheral neuroepithelioma, synovial sarcoma, glioma, astrocytoma, oligodendroglioma, ependymoma, glioblastoma, neuroblastoma, ganglioneuroma, ganglioglioma, medulloblastoma, pineal cell tumor, meningioma, meningiosarcoma, neurofibroma and Schwannoma. DETAILED DESCRIPTION
[0132] Definition and Description
[0133] Unless otherwise specified, the following terms and phrases used herein are intended to have the following meanings. A particular term or phrase should not be considered to be uncertain or unclear in the absence of a special definition, but should be understood according to its ordinary meaning. When a trade name appears in this article, it is intended to refer to its corresponding commercial product or its active ingredient.
[0134] A hyphen ("-") not between two letters or symbols indicates the point of attachment of a substituent. 1-6Alkylcarbonyl - refers to a C- 1-6 However, when the attachment point of the substituent is obvious to those skilled in the art, for example, a halogen substituent, the "-" may be omitted.
[0135] When the group bond is marked with a dashed line When, for example, In the molecule, the wavy line indicates the point of attachment of the group to the rest of the molecule.
[0136] The term "pharmaceutically acceptable" as used herein refers to those compounds, materials, compositions and / or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and animals without excessive toxicity, irritation, allergic response or other problems or complications, commensurate with a reasonable benefit / risk ratio.
[0137] The term "pharmaceutically acceptable salt" refers to salts of the compounds of the present invention, prepared from compounds having specific substituents discovered by the present invention and relatively nontoxic acids or bases. When the compounds of the present invention contain relatively acidic functional groups, base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of base in a pure solution or a suitable inert solvent. Pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amine or magnesium salts or similar salts. When the compounds of the present invention contain relatively basic functional groups, acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of acid in a solution or a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include inorganic acid salts, such as hydrochloric acid, hydrobromic acid, nitric acid, carbonic acid, bicarbonate, phosphoric acid, monohydrogen phosphate, dihydrogen phosphate, sulfuric acid, hydrogen sulfate, hydroiodic acid, phosphorous acid, etc.; and organic acid salts, such as acetic acid, propionic acid, isobutyric acid, trifluoroacetic acid, maleic acid, malonic acid, benzoic acid, succinic acid, suberic acid, fumaric acid, lactic acid, mandelic acid, phthalic acid, benzenesulfonic acid, p-toluenesulfonic acid, citric acid, tartaric acid and methanesulfonic acid, etc.; also include salts of amino acids (such as arginine, etc.), and salts of organic acids such as glucuronic acid. Certain specific compounds of the present invention contain basic and acidic functional groups, and thus can be converted into any base or acid addition salt.
[0138] The pharmaceutically acceptable salts of the present invention can be synthesized by conventional chemical methods from parent compounds containing acid radicals or bases. Generally, the preparation method of such salts is: in water or an organic solvent or a mixture of the two, these compounds in the form of free acid or base are prepared by reacting with a suitable base or acid in a stoichiometric amount.
[0139] The compounds of the present invention may exist in specific geometric or stereoisomeric forms. The present invention contemplates all such compounds, including cis and trans isomers, (-)- and (+)-enantiomers, (R)- and (S)-enantiomers, diastereomers, (D)-isomers, (L)-isomers, and racemic mixtures and other mixtures thereof, such as enantiomerically or diastereomerically enriched mixtures, all of which are within the scope of the present invention. Additional asymmetric carbon atoms may be present in substituents such as alkyl. All of these isomers and their mixtures are included within the scope of the present invention.
[0140] The compounds of the present invention may exist in specific forms. Unless otherwise indicated, the term "tautomer" or "tautomeric form" means that at room temperature, different functional group isomers are in dynamic equilibrium and can quickly convert to each other. If tautomers are possible (such as in solution), the chemical equilibrium of tautomers can be achieved. For example, proton tautomers (proton tautomers) (also known as prototropic tautomers) include interconversions carried out by proton migration, such as keto-enol isomerization and imine-enamine isomerization. Valence isomers (valencetautomers) include interconversions carried out by the reorganization of some bonding electrons. A specific example of keto-enol tautomerization is the interconversion between two tautomers of pentane-2,4-dione and 4-hydroxypent-3-ene-2-one.
[0141] The compounds of the invention may contain unnatural proportions of atomic isotopes on one or more of the atoms that make up the compound. For example, the compounds may be labeled with radioactive isotopes, such as tritium ( 3 H), iodine-125( 125 I) or C-14( 14 C). For another example, deuterium can be substituted for hydrogen to form a deuterated drug. The bond between deuterium and carbon is stronger than the bond between ordinary hydrogen and carbon. Compared with undeuterated drugs, deuterated drugs have the advantages of reducing toxic side effects, increasing drug stability, enhancing therapeutic effects, and extending the biological half-life of drugs. All isotopic composition changes of the compounds of the present invention, whether radioactive or not, are included in the scope of the present invention. "Optional" or "optionally" means that the event or situation described later may but does not necessarily occur, and the description includes the case where the event or situation occurs and the case where the event or situation does not occur.
[0142] The term "substituted" or "substituted by..." means that any one or more hydrogen atoms on a specific atom are replaced by a substituent, which may include deuterium and hydrogen variants, as long as the valence state of the specific atom is normal and the substituted compound is stable. The term "optionally substituted" or "optionally substituted by..." means that it may be substituted or not substituted, and unless otherwise specified, the type and number of the substituents may be any on the basis of chemical practicability.
[0143] When any variable (e.g., R) occurs more than once in a compound's composition or structure, its definition at each occurrence is independent. Thus, for example, if a group is substituted with 1, 2, or 3 R's, the group may be optionally substituted with 1 or 2 or 3 R's, and each occurrence of R' has independent options. In addition, combinations of substituents and / or variants thereof are permitted only if such combinations result in stable compounds.
[0144] When one of the variables is selected from a single bond, it means that the two groups it connects are directly connected, such as When L1 represents a single bond, it means that the structure is actually
[0145] When the substituent is listed without indicating the atom through which it is connected to the substituted group, the substituent can be bonded through any atom thereof. For example, a pyridyl substituent can be bonded to the substituted group through any carbon atom on the pyridine ring.
[0146] When the listed linking group does not indicate its linking direction, its linking direction is arbitrary, for example, The connecting group L is -CH2O-, in which case -CH2O- can connect phenyl and cyclopentyl in the same direction as the reading order from left to right to form It is also possible to connect phenyl and cyclopentyl groups in the opposite direction of reading from left to right to form Combinations of linkers, substituents, and / or variations thereof are permissible only if such combinations result in stable compounds.
[0147] Unless otherwise specified, the number of atoms in a ring is generally defined as the ring member number, for example, "3-6 membered ring" refers to a "ring" having 3-6 atoms arranged around it.
[0148] Unless otherwise specified, the term “C 1-6 "Alkyl" is used to refer to a straight or branched chain saturated hydrocarbon group consisting of 1 to 6 carbon atoms. 1-6 Alkyl groups include C 1-5 , C 1-4 , C 1-3 , C1-2 , C 2-6 , C 2-4 , C6 and C5 alkyl, etc.; it can be monovalent (such as CH3), divalent (-CH2-) or polyvalent (such as C 1-6 Examples of alkyl groups include, but are not limited to, CH3,
[0149] wait.
[0150] Unless otherwise specified, the term “C 1-3 "Alkyl" is used to refer to a straight or branched chain saturated hydrocarbon group consisting of 1 to 3 carbon atoms. 1-3 Alkyl groups include C 1-2 and C 2-3 Alkyl, etc.; it can be monovalent (such as CH3), divalent (-CH2-) or polyvalent (such as C 1-3 Examples of alkyl groups include, but are not limited to, CH3, wait.
[0151] Unless otherwise specified, “C 2-3 "Alkenyl" is used to refer to a straight or branched hydrocarbon group consisting of 2 to 3 carbon atoms containing at least one carbon-carbon double bond, which may be located at any position of the group. 2-3 Alkenyl includes C3 and C2 alkenyl; the C 2-3 The alkenyl group may be monovalent, divalent or polyvalent. 2-3 Examples of alkenyl groups include, but are not limited to wait.
[0152] Unless otherwise specified, “C 2-3 "Alkynyl" is used to refer to a straight or branched hydrocarbon group consisting of 2 to 3 carbon atoms containing at least one carbon-carbon triple bond, which can be located at any position of the group. It can be monovalent, divalent or polyvalent. The C 2-3 Alkynyl groups include C3 and C2 alkynyl groups. 2-3 Examples of alkynyl groups include, but are not limited to wait.
[0153] Unless otherwise specified, the term “C 1-6 "Alkoxy" refers to those alkyl groups containing 1 to 6 carbon atoms which are attached to the rest of the molecule via an oxygen atom. 1-6 Alkoxy includes C 1-4 , C 1-3 , C 1-2 , C 2-6 , C2-4 , C6, C5, C4 and C3 alkoxy, etc. 1-6 Examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy (including n-propoxy and isopropoxy), butoxy (including n-butoxy, isobutoxy, s-butoxy and t-butoxy), pentoxy (including n-pentoxy, isopentoxy and neopentoxy), hexyloxy, and the like.
[0154] Unless otherwise specified, the term “C 1-3 "Alkoxy" refers to those alkyl groups containing 1 to 3 carbon atoms which are attached to the rest of the molecule via an oxygen atom. 1-3 Alkoxy includes C 1-3 , C 1-2 , C 2-3 , C1, C2 and C3 alkoxy, etc. 1-3 Examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy (including n-propoxy and isopropoxy), and the like.
[0155] Unless otherwise specified, the term “C 1-6 "Alkylamino" refers to those alkyl groups containing 1 to 6 carbon atoms which are attached to the rest of the molecule through an amino group. 1-6 Alkylamino groups include C 1-4 , C 1-3 , C 1-2 , C 2-6 , C 2-4 , C6, C5, C4, C3 and C2 alkylamino, etc. 1-6 Examples of alkylamino groups include, but are not limited to, -NHCH3, -N(CH3)2, -NHCH2CH3, -N(CH3)CH2CH3, -N(CH2CH3)(CH2CH3), -NHCH2CH2CH3, -NHCH2(CH3)2, -NHCH2CH2CH2CH3, and the like.
[0156] Unless otherwise specified, the term “C 1-3 "Alkylamino" refers to those alkyl groups containing 1 to 3 carbon atoms which are attached to the rest of the molecule through an amino group. 1-3 Alkylamino groups include C 1-3 , C 1-2 , C 2-3 , C1, C2 and C3 alkylamino, etc. 1-3 Examples of alkylamino groups include, but are not limited to, -NHCH3, -N(CH3)2, -NHCH2CH3, -N(CH3)CH2CH3, -NHCH2CH2CH3, -NHCH2(CH3)2, and the like.
[0157] Unless otherwise specified, the term “C 1-6"Alkylthio" refers to those alkyl groups containing 1 to 6 carbon atoms which are attached to the rest of the molecule via a sulfur atom. 1-6 Alkylthio includes C 1-4 , C 1-3 , C 1-2 , C 2-6 , C 2-4 , C6, C5, C4, C3 and C2 alkylthio, etc. 1-6 Examples of alkylthio groups include, but are not limited to, -SCH3, -SCH2CH3, -SCH2CH2CH3, -SCH2(CH3)2, and the like.
[0158] Unless otherwise specified, the term “C 1-3 "Alkylthio" refers to those alkyl groups containing 1 to 3 carbon atoms which are attached to the rest of the molecule via a sulfur atom. 1-3 Alkylthio includes C 1-3 , C 1-2 , C 2-3 , C1, C2 and C3 alkylthio, etc. 1-3 Examples of alkylthio groups include, but are not limited to, -SCH3, -SCH2CH3, -SCH2CH2CH3, -SCH2(CH3)2, and the like.
[0159] Unless otherwise specified, “C 3-9 "Cycloalkyl" means a saturated cyclic hydrocarbon group consisting of 3 to 9 carbon atoms, which is a monocyclic or bicyclic system. 3-9 Cycloalkyl includes C 3-8 , C 3-7 , C 3-6 , C 3-5 and C 5-6 Cycloalkyl, etc.; it may be monovalent, divalent or polyvalent. 3-9 Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and the like.
[0160] Unless otherwise specified, “C 3-6 "Cycloalkyl" means a saturated cyclic hydrocarbon group consisting of 3 to 6 carbon atoms, which is a monocyclic or bicyclic system. 3-6 Cycloalkyl includes C 3-5 , C 4-5 and C 5-6 Cycloalkyl, etc.; it may be monovalent, divalent or polyvalent. 3-6 Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like.
[0161] Unless otherwise specified, the number of atoms in a ring is generally defined as the ring member number, for example, "3-6 membered ring" refers to a "ring" having 3-6 atoms arranged around it.
[0162] Unless otherwise specified, the term "3-12 membered heterocycloalkyl" by itself or in combination with other terms refers to a saturated cyclic group consisting of 3 to 12 ring atoms, 1, 2, 3 or 4 of which are heteroatoms independently selected from O, S and N, and the rest are carbon atoms, wherein the nitrogen atom is optionally quaternized, and the nitrogen and sulfur heteroatoms are optionally oxidized (i.e., NO and S(O) p , p is 1 or 2). It includes monocyclic, bicyclic and tricyclic systems, wherein bicyclic and tricyclic systems include spirocyclic, paracyclic and bridged rings. In addition, with respect to the "3-12 membered heterocycloalkyl", heteroatoms may occupy the position where the heterocycloalkyl is connected to the rest of the molecule. The 3-12 membered heterocycloalkyl includes 3-10 membered, 3-9 membered, 3-8 membered, 3-6 membered, 3-5 membered, 4-6 membered, 5-6 membered, 4 membered, 5 membered and 6 membered heterocycloalkyls, etc. Examples of 3-12 membered heterocycloalkyl groups include, but are not limited to, azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrothiophenyl (including tetrahydrothiophen-2-yl and tetrahydrothiophen-3-yl, etc.), tetrahydrofuranyl (including tetrahydrofuran-2-yl, etc.), tetrahydropyranyl, piperidinyl (including 1-piperidinyl, 2-piperidinyl and 3-piperidinyl, etc.), piperazinyl (including 1-piperazinyl and 2-piperazinyl, etc.), morpholinyl (including 3-morpholinyl and 4-morpholinyl, etc.), dioxanyl, dithianyl, isoxazolidinyl, isothiazolidinyl, 1,2-oxazinyl, 1,2-thiazinyl, hexahydropyridazinyl, homopiperazinyl, homopiperidinyl or dioxepanyl, wait.
[0163] Unless otherwise specified, the term "3-9 membered heterocycloalkyl" by itself or in combination with other terms refers to a saturated cyclic group consisting of 3 to 9 ring atoms, 1, 2, 3 or 4 of which are heteroatoms independently selected from O, S and N, and the rest are carbon atoms, wherein the nitrogen atom is optionally quaternized, and the nitrogen and sulfur heteroatoms are optionally oxidized (i.e., NO and S(O) p, p is 1 or 2). It includes monocyclic and bicyclic systems, wherein bicyclic systems include spirocyclic, paracyclic and bridged rings. In addition, with respect to the "3-9 membered heterocycloalkyl", heteroatoms may occupy the position where the heterocycloalkyl connects to the rest of the molecule. The 3-9 membered heterocycloalkyl includes 3-6 membered, 4-7 membered, 4 membered, 5 membered, 6 membered, 7 membered, 8 membered, 9 membered heterocycloalkyl, etc. Examples of 3-9 membered heterocycloalkyl groups include, but are not limited to, azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrothiophenyl (including tetrahydrothiophen-2-yl and tetrahydrothiophen-3-yl, etc.), tetrahydrofuranyl (including tetrahydrofuran-2-yl, etc.), tetrahydropyranyl, piperidinyl (including 1-piperidinyl, 2-piperidinyl and 3-piperidinyl, etc.), piperazinyl (including 1-piperazinyl and 2-piperazinyl, etc.), morpholinyl (including 3-morpholinyl and 4-morpholinyl, etc.), dioxanyl, dithianyl, isoxazolidinyl, isothiazolidinyl, 1,2-oxazinyl, 1,2-thiazinyl, hexahydropyridazinyl, homopiperazinyl or homopiperidinyl, etc.
[0164] Unless otherwise specified, the term "3-6 membered heterocycloalkyl" by itself or in combination with other terms refers to a saturated cyclic group consisting of 3 to 6 ring atoms, 1, 2, 3 or 4 of which are heteroatoms independently selected from O, S and N, and the rest are carbon atoms, wherein the nitrogen atom is optionally quaternized, and the nitrogen and sulfur heteroatoms are optionally oxidized (i.e., NO and S(O) p , p is 1 or 2). It includes monocyclic and bicyclic systems, wherein bicyclic systems include spirocyclic, paracyclic and bridged rings. In addition, with respect to the "3-6 membered heterocycloalkyl", heteroatoms may occupy the position where the heterocycloalkyl is connected to the rest of the molecule. The 3-6 membered heterocycloalkyl includes 4-6 membered, 5-6 membered, 4 membered, 5 membered and 6 membered heterocycloalkyl, etc. Examples of 3-6 membered heterocycloalkyl groups include, but are not limited to, azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrothiophenyl (including tetrahydrothiophen-2-yl and tetrahydrothiophen-3-yl, etc.), tetrahydrofuranyl (including tetrahydrofuran-2-yl, etc.), tetrahydropyranyl, piperidinyl (including 1-piperidinyl, 2-piperidinyl and 3-piperidinyl, etc.), piperazinyl (including 1-piperazinyl and 2-piperazinyl, etc.), morpholinyl (including 3-morpholinyl and 4-morpholinyl, etc.), dioxanyl, dithianyl, isoxazolidinyl, isothiazolidinyl, 1,2-oxazinyl, 1,2-thiazinyl, hexahydropyridazinyl, homopiperazinyl or homopiperidinyl, etc.
[0165] Unless otherwise specified, the term "C 6-10 Aromatic rings" and "C 6-10 Aryl" can be used interchangeably, the term "C 6-10 Aromatic ring" or "C 6-10"Aryl" means a cyclic hydrocarbon group composed of 6 to 10 carbon atoms with a conjugated π electron system, which can be a monocyclic, fused bicyclic or fused tricyclic system, in which each ring is aromatic. It can be monovalent, divalent or polyvalent, C 6-10 Aryl includes C 6-9 , C9, C 10 and C6 aryl, etc. 6-10 Examples of aryl groups include, but are not limited to, phenyl, naphthyl (including 1-naphthyl and 2-naphthyl, etc.).
[0166] Unless otherwise specified, the terms "5-12 membered heteroaromatic ring" and "5-12 membered heteroaryl" are used interchangeably in the present invention. The term "5-12 membered heteroaryl" refers to a cyclic group with a conjugated π electron system consisting of 5 to 12 ring atoms, wherein 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from O, S and N, and the rest are carbon atoms. It can be a monocyclic, fused bicyclic or fused tricyclic system, wherein each ring is aromatic. The nitrogen atom is optionally quaternized, and the nitrogen and sulfur heteroatoms are optionally oxidized (i.e., NO and S(O) p , p is 1 or 2). The 5-12 membered heteroaryl group may be attached to the rest of the molecule via a heteroatom or a carbon atom. The 5-12 membered heteroaryl group includes 5-10 membered, 5-9 membered, 5-8 membered, 5-7 membered, 5-6 membered, 5 membered and 6 membered heteroaryl groups, etc. Examples of the 5-12 membered heteroaryl group include, but are not limited to, pyrrolyl (including N-pyrrolyl, 2-pyrrolyl and 3-pyrrolyl, etc.), pyrazolyl (including 2-pyrazolyl and 3-pyrazolyl, etc.), imidazolyl (including N-imidazolyl, 2-imidazolyl, 4-imidazolyl and 5-imidazolyl, etc.), oxazolyl (including 2-oxazolyl, 4-oxazolyl and 5-oxazolyl, etc.), triazolyl (1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, 1H-1,2,4-triazolyl and 4H-1,2,4-triazolyl, etc.), tetrazolyl, isoxazolyl (3-isoxazolyl, 4-isoxazolyl and 5-isoxazolyl, etc.), thiazolyl (including 2-thiazolyl, 4- thiazolyl and 5-thiazolyl, etc.), furanyl (including 2-furanyl and 3-furanyl, etc.), thienyl (including 2-thienyl and 3-thienyl, etc.), pyridyl (including 2-pyridyl, 3-pyridyl and 4-pyridyl, etc.), pyrazinyl, pyrimidinyl (including 2-pyrimidinyl and 4-pyrimidinyl, etc.), benzothiazolyl (including 5-benzothiazolyl, etc.), purinyl, benzimidazolyl (including 2-benzimidazolyl, etc.), benzoxazolyl, indolyl (including 5-indolyl, etc.), isoquinolyl (including 1-isoquinolyl and 5-isoquinolyl, etc.), quinoxalinyl (including 2-quinoxalinyl and 5-quinoxalinyl, etc.), or quinolyl (including 3-quinolyl and 6-quinolyl, etc.).
[0167] Unless otherwise specified, the terms "5-6 membered heteroaromatic ring" and "5-6 membered heteroaryl" are used interchangeably in the present invention. The term "5-6 membered heteroaryl" refers to a monocyclic group with a conjugated π electron system consisting of 5 to 6 ring atoms, wherein 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from O, S and N, and the rest are carbon atoms. The nitrogen atom is optionally quaternized, and the nitrogen and sulfur heteroatoms are optionally oxidized (i.e., NO and S(O) p , p is 1 or 2). The 5-6 membered heteroaryl can be attached to the rest of the molecule via a heteroatom or a carbon atom. The 5-6 membered heteroaryl includes 5-membered and 6-membered heteroaryl. Examples of the 5-6 membered heteroaryl include, but are not limited to, pyrrolyl (including N-pyrrolyl, 2-pyrrolyl and 3-pyrrolyl, etc.), pyrazolyl (including 2-pyrazolyl and 3-pyrazolyl, etc.), imidazolyl (including N-imidazolyl, 2-imidazolyl, 4-imidazolyl and 5-imidazolyl, etc.), oxazolyl
[0168] (including 2-oxazolyl, 4-oxazolyl and 5-oxazolyl, etc.), triazolyl (1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, 1H-1,2,4-triazolyl and 4H-1,2,4-triazolyl, etc.), tetrazolyl, isoxazolyl (3-isoxazolyl, 4-isoxazolyl and 5-isoxazolyl, etc.), thiazolyl (including 2-thiazolyl, 4-thiazolyl and 5-thiazolyl, etc.), furanyl (including 2-furanyl and 3-furanyl, etc.), thienyl (including 2-thienyl and 3-thienyl, etc.), pyridyl (including 2-pyridyl, 3-pyridyl and 4-pyridyl, etc.), pyrazinyl or pyrimidinyl (including 2-pyrimidinyl and 4-pyrimidinyl, etc.).
[0169] Unless otherwise specified, the terms "5-10 membered heteroaromatic ring" and "5-10 membered heteroaryl" are used interchangeably in the present invention, and the term "5-9 membered heteroaryl" refers to a monocyclic group with a conjugated π electron system consisting of 5 to 10 ring atoms, wherein 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from O, S and N, and the rest are carbon atoms. The nitrogen atom is optionally quaternized, and the nitrogen and sulfur heteroatoms are optionally oxidized (i.e., NO and S(O) p, p is 1 or 2). 5-10 yuan of heteroaryl can be connected to the rest of the molecule by heteroatom or carbon atom. The 5-10 yuan of heteroaryl includes 5 yuan, 6 yuan, 7 yuan, 8 yuan, 9 yuan, 10 yuan of heteroaryl. The example of the 5-10 yuan of heteroaryl includes but is not limited to pyrrolyl (including N-pyrrolyl, 2-pyrrolyl and 3-pyrrolyl, etc.), pyrazolyl (including 2-pyrazolyl and 3-pyrazolyl, etc.), imidazolyl (including N-imidazolyl, 2-imidazolyl, 4-imidazolyl and 5-imidazolyl, etc.), oxazolyl (including 2-oxazolyl, 4-oxazolyl and 5-oxazolyl, etc.), triazolyl (1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, 1H-1,2,4-triazolyl, etc.), 1-H-1,2,4-triazolyl, etc.), tetrazolyl, isoxazolyl (3-isoxazolyl, 4-isoxazolyl and 5-isoxazolyl), thiazolyl (including 2-thiazolyl, 4-thiazolyl and 5-thiazolyl), furyl (including 2-furyl and 3-furyl), thienyl (including 2-thienyl and 3-thienyl), pyridyl (including 2-pyridyl, 3-pyridyl and 4-pyridyl), pyrazinyl or pyrimidinyl (including 2-pyrimidinyl and 4-pyrimidinyl).
[0170] Unless otherwise specified, C n-n+m or C n -C n+m Any specific case including n to n+m carbons, such as C 1-12 Including C1, C2, C3, C4, C5, C6, C7, C8, C9, C 10 , C 11 , and C 12 , also includes any range from n to n+m, such as C 1-12 Including C 1-3 , C 1-6 , C 1-9 , C 3-6 , C 3-9 , C 3-12 , C 6-9 , C 6-12 , and C 9-12 etc.; similarly, n-membered to n+m-membered means that the number of atoms in the ring is n to n+m, for example, 3-12-membered ring includes 3-membered ring, 4-membered ring, 5-membered ring, 6-membered ring, 7-membered ring, 8-membered ring, 9-membered ring, 10-membered ring, 11-membered ring, and 12-membered ring, and also includes any range from n to n+m, for example, 3-12-membered ring includes 3-6-membered ring, 3-9-membered ring, 5-6-membered ring, 5-7-membered ring, 5-10-membered ring, 6-7-membered ring, 6-8-membered ring, 6-9-membered ring and 6-10-membered ring, etc.
[0171] The term "leaving group" refers to a functional group or atom that can be replaced by another functional group or atom through a substitution reaction (e.g., an affinity substitution reaction). For example, representative leaving groups include trifluoromethanesulfonate; chlorine, bromine, iodine; sulfonate groups, such as mesylate, tosylate, p-brosylate, p-toluenesulfonate, etc.; acyloxy groups, such as acetoxy, trifluoroacetoxy, etc.
[0172] The term "protecting group" includes, but is not limited to, "amino protecting group", "hydroxy protecting group" or "thiol protecting group". The term "amino protecting group" refers to a protecting group suitable for preventing side reactions at the amino nitrogen position. Representative amino protecting groups include, but are not limited to: formyl; acyl, such as alkanoyl (such as acetyl, trichloroacetyl or trifluoroacetyl); alkoxycarbonyl, such as tert-butyloxycarbonyl (Boc); arylmethoxycarbonyl, such as benzyloxycarbonyl (Cbz) and 9-fluorenylmethoxycarbonyl (Fmoc); arylmethyl, such as benzyl (Bn), trityl (Tr), 1,1-bis-(4'-methoxyphenyl)methyl; silyl, such as trimethylsilyl (TMS) and tert-butyldimethylsilyl (TBS), etc. The term "hydroxy protecting group" refers to a protecting group suitable for preventing side reactions of the hydroxyl group. Representative hydroxy protecting groups include, but are not limited to, alkyl groups such as methyl, ethyl and tert-butyl; acyl groups such as alkanoyl (e.g., acetyl); arylmethyl groups such as benzyl (Bn), p-methoxybenzyl (PMB), 9-fluorenylmethyl (Fm) and diphenylmethyl (diphenylmethyl, DPM); silyl groups such as trimethylsilyl (TMS) and tert-butyldimethylsilyl (TBS), and the like.
[0173] The pharmaceutical composition of the present invention is characterized by comprising a compound of formula (I) or (IA) or (IB) or (IC), a compound listed in the present invention, or a compound of the Examples, and a pharmaceutically acceptable carrier, adjuvant, or vehicle. The compound in the composition of the present invention can be used to treat cancer, particularly prostate cancer.
[0174] Pharmaceutical excipients can be pharmaceutically acceptable carriers, adjuvants, or vehicles, which, as used in the present invention, include any solvents, diluents, or other liquid excipients, dispersants or suspending agents, surfactants, isotonic agents, thickeners, emulsifiers, preservatives, solid binders or lubricants, etc., suitable for the specific target dosage form.
[0175] It will be appreciated by those skilled in the art that some compounds of formula (I) may contain one or more chiral centers and therefore may exist as two or more stereoisomers. Therefore, the compounds of the present invention may exist as single stereoisomers (e.g. enantiomers, diastereomers) and mixtures thereof in any proportion, such as racemates, and, where appropriate, as tautomers and geometric isomers.
[0176] The term "stereoisomer" as used herein refers to compounds that have identical chemical constitution but differ in the arrangement of the atoms or groups in space. Stereoisomers include enantiomers, diastereomers, conformational isomers, and the like.
[0177] As used herein, the term "enantiomers" refers to two stereoisomers of a compound that are non-superimposable mirror images of one another.
[0178] The term "diastereomer" as used herein refers to stereoisomers having two or more chiral centers and whose molecules are not mirror images of each other. Diastereomers have different physical properties, such as melting points, boiling points, spectral properties or biological activities. Mixtures of diastereomers can be separated by high resolution analytical methods such as electrophoresis and chromatography such as HPLC.
[0179] Stereochemical definitions and conventions may be followed in SP Parker, ed., McGraw-Hill Dictionary of Chemical Terms (1984) McGraw-Hill Book Company, New York; and Eliel, E. and Wilen, S., "Stereochemistry of Organic Compounds", John Wiley & Sons, Inc., New York, 1994. Many organic compounds exist in optically active forms, i.e., they have the ability to rotate the plane of plane polarized light. In describing optically active compounds, the prefixes D and L or R and S are used to indicate the absolute configuration of the molecule about its chiral center. The prefixes d and l or (+) and (-) are used to indicate the sign of the rotation of plane polarized light by the compound, where (-) or l indicates that the compound is left-handed. Compounds prefixed with (+) or d are right-handed. For a given chemical structure, these stereoisomers are identical except that they are mirror images of each other. Specific stereoisomers may also be referred to as enantiomers, and mixtures of such isomers are often referred to as enantiomeric mixtures. A 50:50 mixture of enantiomers is called a racemic mixture or racemate, which may occur when there is no stereoselectivity or stereospecificity in a chemical reaction or process. The terms "racemic mixture" and "racemate" refer to an equimolar mixture of two enantiomers that are optically inactive.
[0180] The racemic mixture can be used in its own form or split into individual isomers. Stereochemically pure compounds or mixtures enriched in one or more isomers can be obtained by splitting. Methods for separating isomers are well known (see Allinger NL and Eliel EL, "Topics in Stereochemistry", Vol. 6, Wiley Interscience, 1971), including physical methods, such as chromatography using chiral adsorbents. Individual isomers in chiral form can be prepared from chiral precursors. Alternatively, the individual isomers can be chemically separated from the mixture by forming diastereomeric salts with chiral acids (e.g., individual enantiomers of 10-camphorsulfonic acid, camphoric acid, α-bromocamphoric acid, tartaric acid, diacetyltartaric acid, malic acid, pyrrolidone-5-carboxylic acid, etc.), fractionally crystallizing the salts, then freeing one or both of the resolved bases, and optionally repeating this process to obtain one or both isomers that are substantially free of the other isomer, i.e., the desired stereoisomers having an optical purity of, for example, at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 99.5% by weight. Alternatively, as is well known to those skilled in the art, the racemates can be covalently linked to chiral compounds (auxiliaries) to obtain diastereomers.
[0181] The term "tautomer" or "tautomeric form" as used herein refers to structural isomers of different energies that are interconvertible via a low energy barrier. For example, proton tautomers (also known as prototropic tautomers) include interconversions via proton migration, such as keto-enol and imine-enamine isomerizations. Valence tautomers include interconversions via reorganization of some of the bonding electrons.
[0182] As used herein, the term "treatment" refers to the administration of one or more drug substances, particularly compounds of formula (I) and / or pharmaceutically acceptable salts thereof, to an individual suffering from a disease or symptoms of the disease, in order to cure, alleviate, mitigate, alter, cure, improve, ameliorate or affect the disease or symptoms of the disease. As used herein, the term "prevention" refers to the administration of one or more drug substances, particularly compounds of formula (I) and / or pharmaceutically acceptable salts thereof, to an individual with a physique susceptible to the disease, in order to prevent the individual from suffering from the disease. When referring to a chemical reaction, the terms "treating", "contacting" and "reacting" refer to the addition or mixing of two or more reagents under appropriate conditions to produce the indicated and / or desired product. It should be understood that the reaction that produces the indicated and / or desired product may not necessarily result directly from the combination of the two reagents initially added, that is, there may be one or more intermediates generated in the mixture, which ultimately lead to the formation of the indicated and / or desired product.
[0183] The term "effective amount" as used herein refers to an amount that is generally sufficient to produce a beneficial effect on an individual. The effective amount of the compound of the present invention can be determined by conventional methods (e.g., modeling, dose escalation studies or clinical trials) in combination with conventional influencing factors (e.g., mode of administration, pharmacokinetics of the compound, severity and course of the disease, individual medical history, individual health status, individual response to the drug, etc.). The compound of the present invention can be prepared by a variety of synthetic methods well known to those skilled in the art, including the specific embodiments listed below, embodiments formed by combining them with other chemical synthesis methods, and equivalent substitutions well known to those skilled in the art, and preferred embodiments include but are not limited to embodiments of the present invention.
[0184] The solvent used in the present invention is commercially available.
[0185] Compounds are named according to the conventional nomenclature in the art or using The software names were used, and commercially available compounds were named using the supplier's catalog names.
[0186] The present application is described in detail below by way of examples, but it is not intended that there is any adverse limitation to the present application. The present application has been described in detail herein, and its specific embodiments are also disclosed therein. It will be apparent to those skilled in the art that various changes and modifications can be made to the specific embodiments of the present application without departing from the spirit and scope of the present application.
[0187] Preparation of intermediates
[0188] Reference Example 1: Preparation of Intermediate I-1
[0189]
[0190] Under stirring at 0°C, tert-butyl bromoacetate (23.00 g, 120 mmol) was added to a mixture of 5-hexen-1-ol (10.00 g, 99.8 mmol), tetrabutylammonium hydrogensulfate (10.00 g, 99.8 mmol), 40% potassium hydroxide aqueous solution (135 mL) and toluene (135 mL). The reaction mixture was stirred at 0°C for 1 hour, and then the temperature was raised to room temperature and the reaction was continued for 24 hours. The reaction system was poured into ice water (300 mL) and extracted with ethyl acetate (200 mL×4). The organic phases were combined, washed with saturated brine (200 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the residue was purified by silica gel chromatography to obtain intermediate I-1.
[0191] 1 H NMR (400MHz, CDCl3) δ5.72-5.86(m,1H),4.90-5.04(m,2H),3.94(s,2H),3.51(t,J=6.54Hz,2 H),2.03-2.12(m,2H),1.59-1.67(m,2H),1.49-1.52(m,1H),1.47(s,9H),1.42-1.46(m,1H).
[0192] Reference Example 2: Preparation of Intermediate I-2
[0193]
[0194] At 25°C, potassium osmate dihydrate (258.3 mg, 0.70 mmol) was added to an acetone (250 mL) solution of intermediate I-1 (5.00 g, 23.33 mmol), and then a water (75 mL) solution of N-methyl-N-morpholine oxide (8.30 g, 70 mmol) was added to the mixture. Under nitrogen protection, the reaction mixture was stirred at 25°C for 18 hours, and sodium periodate (258.3 mg, 0.70 mmol) was added to the reaction solution and the reaction was continued for 3 hours. The reaction system was poured into water (200 mL) and extracted with dichloromethane (100 mL×4). The organic phases were combined, washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the residue was purified by silica gel chromatography to obtain intermediate I-2.
[0195] 1H NMR (400MHz, CDCl3) δ9.78 (t, J = 1.65Hz, 1H), 3.92-3.96 (m, 2H), 3.50-3.58 ( m,2H),2.46-2.66(m,2H),1.72-1.81(m,2H),1.62-1.71(m,2H),1.48(s,9H).
[0196] Reference Example 3: Preparation of Intermediate I-3
[0197]
[0198] At room temperature, acetic acid (1.39 g, 23.12 mmol) was added to a solution of intermediate I-2 (2.50 g, 11.56 mmol) and methyl para-aminobenzoate (1.75 g, 11.56 mmol) in 1,2-dichloroethane (50 mL), and sodium triacetoxyborohydride (4.90 g, 23.12 mmol) was added after stirring for ten minutes. The reaction mixture was stirred at room temperature for 18 hours. Saturated sodium bicarbonate was poured into the reaction system, the pH value of the reaction solution was adjusted to 8, and extracted with dichloromethane (30 mL × 4). The organic phases were combined, washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the residue was purified by silica gel chromatography to obtain intermediate I-3.
[0199] 1 H NMR (400MHz, CDCl3) δ7.82-7.88(m,2H),6.51-6.59(m,2H),3.94-3.97(m,2H),3.84(s,3H) ,3.49-3.59(m,2H),3.14-3.24(m,2H),1.62-1.80(m,4H),1.49-1.57(m,2H),1.48(s,9H).
[0200] Reference Example 4: Preparation of Intermediate I-4
[0201]
[0202] Intermediate I-3 (500 mg, 1.43 mmol) was dissolved in dichloromethane (2 mL), trifluoroacetic acid (1 mL) was added at room temperature, and the mixture was stirred at room temperature for 4 hours. The reaction solution was concentrated to obtain a crude intermediate I-4. The crude product was used directly in the next step without further purification.
[0203] Reference Example 5: Preparation of Intermediate I-5
[0204]
[0205] At room temperature, 4-methyltetrahydro-2H-pyran-4-carboxaldehyde (1g, 7.81mmol) and D-phenylglycinol (1.6g, 11.72mmol) were dissolved in anhydrous dichloromethane (20mL). The reaction solution was replaced with nitrogen three times and then reacted at room temperature for 5 hours. The reaction solution was cooled to zero degrees, trimethylsilyl cyanide (1.55g, 15.62mmol) was slowly added, and stirred at room temperature overnight. 3N hydrochloric acid (15mL) was added, and the reaction solution was continued to stir at room temperature for 3 hours. Dichloromethane extraction (15mL×3), the organic layer was washed with water (20mL), washed with saturated brine (20mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the residue was purified by silica gel chromatography to obtain intermediate I-5.
[0206] LC-MS(ESI)[M+H] + 275.2.
[0207] Reference Example 6: Preparation of Intermediate I-6
[0208]
[0209] At room temperature, the intermediate I-5 (1g, 3.64mmol) was dissolved in anhydrous dichloromethane and methanol (10mL / 5mL), nitrogen was protected, the temperature was lowered to zero degrees, and lead tetraacetate (2.42g, 5.47mmol) was added. The reaction solution was stirred at room temperature for 16 hours. The reaction system was poured into phosphate buffer (20mL, pH=7) and extracted with dichloromethane (20mL×2). The organic phases were combined, washed with saturated brine (30mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the residue was purified by silica gel chromatography to obtain the intermediate I-6.
[0210] LC-MS(ESI)[M+H] + 243.2.
[0211] Reference Example 7: Preparation of Intermediate I-7
[0212]
[0213] At room temperature, intermediate I-6 (300 mg, 1.24 mmol) was dissolved in concentrated hydrochloric acid (3 mL), heated to 100°C and stirred for 2 hours, and then the reaction solution was concentrated under reduced pressure to obtain intermediate I-7. The crude product was directly used in the next step without further purification.
[0214] Reference Example 8: Preparation of Intermediate I-8
[0215]
[0216] At room temperature, the intermediate I-7 (200 mg) was dissolved in a 1M aqueous sodium hydroxide solution (20 mL), and di-tert-butyl dicarbonate (504 mg, 2.31 mmol) was added. After the reaction solution was stirred at room temperature for 16 hours, the pH was adjusted to 3 with 1N hydrochloric acid, and extracted with ethyl acetate (20 mL × 2). The organic phases were combined, washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to remove the organic solvent to obtain the intermediate I-8. The crude product was used directly in the next step without further purification.
[0217] Reference Example 9: Preparation of Intermediate I-9
[0218]
[0219] 4-bromobenzonitrile (20.0 g, 110 mmol) was dissolved in dimethylacetamide (200 mL) at room temperature, and 4-methylthiazole (21.8 g, 220 mmol), potassium acetate (21.6 g, 220 mmol) and palladium acetate (247 mg, 1.1 mmol) were added in sequence. The reaction solution was heated to 150 °C and stirred for 16 hours under argon protection. After cooling to room temperature, water (500 mL) and ethyl acetate (300 mL) were added, the organic phase was separated, the aqueous phase was further extracted with ethyl acetate (300 mL × 2), the organic phases were combined, washed with saturated brine (100 mL × 2), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the residue was purified by silica gel chromatography to obtain intermediate I-9.
[0220] Reference Example 10: Preparation of Intermediate I-10
[0221]
[0222] The intermediate I-9 (15.2 g, 75.9 mmol) was dissolved in tetrahydrofuran (450 mL), the reaction mixture was cooled to 0 ° C, and lithium aluminum hydride (5.77 g, 152 mmol) was added under stirring. The reaction solution was heated to 60 ° C and stirred overnight. After the reaction was completed, it was cooled to room temperature, and water (6 mL) and 1.5 M sodium hydroxide aqueous solution (6 mL) were added in sequence. After stirring at room temperature for 30 minutes, it was filtered through diatomaceous earth, and the filtrate was concentrated under reduced pressure to obtain the intermediate I-10. The crude product was directly used in the next reaction without further purification.
[0223] LC-MS(ESI)[M+H-NH3] + 188.2.
[0224] Reference Example 11: Preparation of Intermediate I-11
[0225]
[0226] Boc-L-hydroxyproline (13.70 g, 59.2 mmol) was dissolved in N, N-dimethylformamide (60 mL), and then the temperature was lowered to 0°C, followed by the addition of intermediate I-10 (12.10 g), O-(7-azabenzotriazole-1-yl)-N, N, N'-tetramethyluronium hexafluorophosphate (27.00 g, 71.0 mmol) and N, N-diisopropylethylamine (15.30 g, 118 mmol). The reaction solution was stirred at room temperature for 2 hours, and water (600 mL) was added. The mixture was extracted with ethyl acetate (100 mL × 3), and the organic phases were combined, washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the residue was purified by silica gel chromatography to obtain intermediate I-11.
[0227] LC-MS(ESI)[M+H] + 418.2.
[0228] Reference Example 12: Preparation of Intermediate I-12
[0229]
[0230] The intermediate I-11 (21.10 g, 50.5 mmol) was dissolved in a methanol solution of hydrogen chloride (3 M, 50 mL), the reaction solution was heated to 30 °C and stirred for 1 hour, filtered, and the filter cake was washed with ethyl acetate (50 mL) and purified by reverse phase chromatography to obtain the intermediate I-12.
[0231] LC-MS(ESI)[M+H] + 318.2.
[0232] 1 H NMR (400MHz, DMSO-d6) δ9.24(t,J=5.8Hz,1H),9.00(d,J=6.9Hz,1H),7.47(d,J=8.2Hz,2H),7.38(d,J=8.2Hz,2H),5.57(d,J= 2.5Hz,1H),4.47–4.31(m,4H),3.34–3.29(m,2H),3.09(d,J=12.1Hz,1H),2.45(s,3H),2.37–2.29(m,1H),1.96–1.88(m,1H).
[0233] Reference Example 13: Preparation of Intermediate I-13
[0234]
[0235] At room temperature, the intermediate I-8 (100 mg) was dissolved in N, N-dimethylformamide (3 mL), and N, N-diisopropylethylamine (142 mg, 1.098 mmol) and O-(7-azabenzotriazole-1-yl)-N, N, N'-tetramethyluronium hexafluorophosphate (205 mg, 0.549 mmol) were added. Then, the intermediate I-12 (116 mg, 0.366 mmol) was added. After the reaction mixture was stirred at room temperature for 16 hours, the reaction system was poured into water (15 mL) and extracted with ethyl acetate (15 mL×2). The organic phases were combined, washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the residue was purified by silica gel chromatography to obtain the intermediate I-13.
[0236] LC-MS(ESI)[M+H] + 573.3.
[0237] Reference Example 14: Preparation of Intermediate I-14
[0238]
[0239] At room temperature, intermediate I-13 (50 mg, 0.087 mmol) was dissolved in dichloromethane (1 mL), trifluoroacetic acid (1 mL) was slowly added, and stirred at room temperature for 2 hours. The reaction solution was concentrated and the organic solvent was removed to obtain the crude product intermediate I-14. The crude product was directly used in the next step without further purification.
[0240] LC-MS(ESI)[M+H] + 473.3.
[0241] Reference Example 15: Preparation of Intermediate I-15
[0242]
[0243] At room temperature, the intermediate I-14 (50 mg) was dissolved in N, N-dimethylformamide (3 mL), and N, N-diisopropylethylamine (41 mg, 0.318 mmol), O-(1H-benzotriazole-1-yl)-N, N, N', N'-tetramethyluronium tetrafluorophosphate (51 mg, 0.159 mmol) and the intermediate I-4 (31 mg) were added. After the reaction mixture was stirred at room temperature for 16 hours, the reaction system was poured into water (15 mL) and extracted with ethyl acetate (15 mL × 2). The organic phases were combined, washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the residue was purified by silica gel chromatography to obtain the intermediate I-15.
[0244] LC-MS(ESI)[M+H] +750.4.
[0245] Reference Example 16: Preparation of Intermediate I-16
[0246]
[0247] At room temperature, the intermediate I-15 (30 mg, 0.050 mmol) was dissolved in tetrahydrofuran / water / methanol (2 mL / 2 mL / 2 mL), and lithium hydroxide monohydrate (17 mg, 0.4 mmol) was added, and the mixture was heated to 40°C for 16 hours. 10 mL of water was added, and ethyl acetate (15 mL) was extracted, and the pH of the aqueous layer was adjusted to 3 with 1N hydrochloric acid. The aqueous phase was concentrated under reduced pressure and purified by reverse phase column chromatography to obtain the intermediate I-16.
[0248] LC-MS(ESI)[M+H] + 736.4.
[0249] Reference Example 17: Preparation of Intermediate I-17
[0250]
[0251] At room temperature, 1,4-butanediol (20 g, 221.9 mmol), tert-butyl bromoacetate (30 g, 153.8 mmol) and tetrabutylammonium chloride (4.5 g, 16.2 mmol) were dissolved in dichloromethane (400 mL), and then sodium hydroxide aqueous solution (300 mL, 35% w / w) was added. The reaction mixture was stirred at room temperature overnight. The mixture was poured into water (400 mL), the organic phase was separated, and the aqueous phase was extracted with dichloromethane (300 mL×2). The organic phases were combined, washed with water (200 mL) and saturated brine (200 mL), and dried over anhydrous sodium sulfate. Filtered, the filtrate was concentrated under reduced pressure to obtain a crude product, and the crude product was separated and purified by silica gel chromatography to obtain intermediate I-17.
[0252] 1 H NMR (400MHz, CDCl3) δ3.95(s,2H),3.72–3.64(m,2H),3.59–3.54(m,2H),2.05(s,1H),1.77–1.65(m,4H),1.48(s,9H).
[0253] Reference Example 18: Preparation of Intermediate I-18
[0254]
[0255] At room temperature, intermediate I-17 (9.587 g, 46.93 mmol) and triethylamine (23.74 g, 234.6 mmol) were dissolved in dichloromethane (150 mL). The reaction mixture was cooled to 0 ° C, and then a solution of p-toluenesulfonyl chloride (17.89 g, 93.84 mmol) in dichloromethane (53.0 mL) was added dropwise. After the addition was completed, the reaction mixture was slowly warmed to room temperature and stirred to react overnight. Water (50 mL) was added to the reaction mixture for dilution, and then extracted with dichloromethane (50.0 mL × 3). The organic phases were combined, washed with saturated brine (50.0 mL), and dried over anhydrous sodium sulfate. Filter, and the filtrate was concentrated under reduced pressure to obtain a crude product, which was separated and purified by silica gel chromatography to obtain intermediate I-18.
[0256] LCMS(ESI)[M+H-56] + 303.1.
[0257] Reference Example 19: Preparation of Intermediate I-19
[0258]
[0259] At room temperature, intermediate I-18 (11.82 g, 33.0 mmol) and benzyl 4-hydroxybenzoate (9.04 g, 39.6 mmol) were dissolved in N,N-dimethylformamide (150 mL), and potassium carbonate (9.12 g, 66.0 mmol) was added. The reaction mixture was stirred at 70 ° C overnight. Cooled to room temperature, diluted with water (300 mL), and extracted with ethyl acetate (100 mL × 3). The organic phases were combined, washed with water (100 mL) and saturated brine (50 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to obtain a crude product, which was separated and purified by silica gel chromatography to obtain intermediate I-19.
[0260] LCMS (ESI) [M+NH3+H] + 432.2.
[0261] Reference Example 20: Preparation of Intermediate I-20
[0262]
[0263] At room temperature, intermediate I-19 (5.00 g, 12.1 mmol) was dissolved in methanol (50.0 mL), and palladium carbon (0.5 g, 10% w / w) was added. The reaction mixture was stirred at room temperature overnight under a hydrogen atmosphere. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to obtain intermediate I-20, which was used directly in the next step without purification.
[0264] Reference Example 21: Preparation of Intermediate I-21
[0265]
[0266] At room temperature, the intermediate I-20 (70.00 mg) and reagent 1 (54.75 mg, 0.20 mmol) were dissolved in dichloromethane (3 mL), and N, N-diisopropylethylamine (77.40 mg, 0.6 mmol) and O-benzotriazole-N, N, N', N'-tetramethyluronium tetrafluoroborate (96.30 mg, 0.30 mmol) were added in sequence. After the reaction mixture was stirred at room temperature for 16 hours, the reaction system was poured into water (20 mL) and extracted with ethyl acetate (20 mL × 3). The organic phases were combined, washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to remove the organic solvent to obtain a crude product. The crude product was separated and purified by silica gel chromatography to obtain the intermediate I-21.
[0267] LC-MS(ESI)[M+H-56] + 529.6.
[0268] Reference Example 22: Preparation of Intermediate I-22
[0269]
[0270] At room temperature, intermediate I-21 (80.00 mg, 0.13 mmol) was dissolved in dichloromethane (3 mL), trifluoroacetic acid (1 mL) was slowly added, and stirred at room temperature for 90 minutes. The reaction solution was concentrated and the organic solvent was removed to obtain the crude intermediate I-22. The crude product was directly used in the next step without further purification.
[0271] Example 1: Preparation of Compound 1
[0272]
[0273] At room temperature, the intermediate I-16 (25 mg, 0.056 mmol) was dissolved in N, N-dimethylformamide (3 mL), and N, N-diisopropylethylamine (13 mg, 0.102 mmol), O-(1H-benzotriazole-1-yl)-N, N, N', N'-tetramethyluronium tetrafluorophosphate (16 mg, 0.051 mmol) and reagent 1 (10 mg, 0.034 mmol) were added. After the reaction mixture was stirred at room temperature for 16 hours, the reaction system was poured into water (15 mL) and extracted with ethyl acetate (15 mL×2). The organic phases were combined, washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to remove the organic solvent to obtain a crude product. The crude product was purified by preparative HPLC to obtain compound 1.
[0274] LC-MS(ESI)[M+H] + 996.3.
[0275] 1 H NMR (400MHz, CD3OD) δ8.89-8.81(m,1H),7.71(d,J=8.8Hz,1H),7.65-7.59(m,2H),7.46-7.36(m,4H),7.11(d,J=2.4Hz,1H),6.96(dd,J=2.4,8.8 Hz,1H),6.64-6.57(m,2H),4.78-4.73(m,1H),4.63-4.55(m,2H),4.53- 4.45(m,2H),4.39-4.32(m,1H),4.26(s,1H),4.13-4.08(m,1H),4.03-3. 91(m,2H),3.91-3.85(m,1H),3.84-3.78(m,1H),3.72(d,J=11.0Hz,2H) ,3.62-3.52(m,4H),3.16(t,J=6.8Hz,2H),2.48-2.43(m,3H),2.29-2.20 (m,1H),2.11-2.02(m,1H),1.84-1.73(m,1H),1.72-1.64(m,4H),1.61-1 .49(m,2H),1.44-1.31(m,2H),1.25(d,J=1.4Hz,6H),1.22-1.14(m,9H).
[0276] Example 2: Preparation of Compound 2
[0277]
[0278] Intermediate I-22 (35 mg), intermediate I-14 (35 mg) and N, N-diisopropylethylamine (27 mg, 0.21 mmol) were mixed in dichloromethane (2 mL), O-benzotriazole-N, N, N', N'-tetramethyluronium tetrafluoroborate (33 mg, 0.10 mmol) was added, and the mixture was stirred at room temperature for 16 hours. The reaction solution was concentrated and purified by preparative HPLC to obtain compound 2.
[0279] LC-MS(ESI)[M+H] + 983.6.
[0280] 1H NMR (400MHz, CD3OD) δ8.76 (s, 1H), 7.70–7.66 (m, 2H), 7.62 (d, J = 8.7Hz, 1H), 7.38–7.30 (m, 4H), 7.03 (d, J = 2.4Hz, 1H),6.91–6.86(m,3H),4.66(s,1H),4.47(m,1H),4.41(m,2H),4.26(m,1H),4.18(s,1H),4.04(s,1H),4.00(t,J=6 .2Hz,2H),3.92(d,J=7.9Hz,2H),3.79(m,1H),3.73(m,1H),3.65–3.60(m,2H),3.55(m,2H),3.48(m,2H),2.36(s,3 H),2.14(m,1H),1.98(m,1H),1.84(m,2H),1.74(m,2H),1.35–1.20(m,4H),1.18(s,6H),1.12(s,6H),1.07(s,3H).
[0281] Experimental Example 3: Androgen Receptor In-Cell-Western Assay
[0282] This assay evaluates compound performance in Lncap cells. Intracellular androgen receptor was measured by In-Cell-Western according to the following assay procedure.
[0283] In a poly-D-Lysin pretreated 96-well cell culture plate (Corning 3599), LNcap cells were seeded at 30,000 cells / well in LNcap cell assay medium [DMEM containing phenol red (Gibco catalog number: 11995065); fetal bovine serum FBS (Gibco catalog number: 10099141C)] at a volume of 100 μl / well. The cells were cultured for at least two days.
[0284] 1. First, treat the cells with the compound. Use DMSO and cell culture medium to make a gradient dilution of the compound so that the DMSO contained in the cell culture plate is diluted to 0.5% - use polypropylene plates according to the following scheme:
[0285] (1)(i) Prepare a 200× stock solution plate in DMSO; (ii) Dilute the 10mM stock solution 1:4 with DMSO (10μl stock solution + 40ul DMSO) = 2000μM and enter the second row; (iii) Perform a 1:4 gradient dilution (10μl protac + 40μl DMSO) from the second row to the ninth row, leaving the first row for the 2000μM reference compound and the tenth row for DMSO. (iv) A total of 8 concentrations (the final concentrations on the 200× plate are 2000μM, 400μM, 80μM, etc.). (2)(i) Prepare a 3× stock solution in culture medium; (ii) Transfer 3μL of the 200× stock solution to 197μl culture medium (using a 12-channel pipette, from row 1 to row 10), i.e., a 3× stock solution plate. (iii) Mix the stock solution plate evenly. (3) (i) Replace the culture medium of Vcap cells with fresh culture medium, 100 μl volume of culture medium. (ii) Transfer the mixed 3× stock solution to the cell culture plate (use a 12-channel pipette to transfer 50 μl of stock solution from row 1 to row 10). (iii) Culture the cells for 24 hours.
[0286] 2. Detect the expression level of androgen receptor in cells after compound treatment, and measure it according to the following method.
[0287] (1)(i) Add an equal volume of 8% paraformaldehyde to the cell culture plate to fix the cells. Discard the fixative in the cell plate and wash three times with PBS. (ii) Prepare Triton solution (dilute the stock solution 1:1000). Discard the solution in the cell plate and add 200μl of Triton dilution to each well. (iii) Prepare 2× blocking solution (10× blocking stock solution diluted 1:4). Discard the solution in the cell plate and add 100μl of 2× blocking solution to each well. (iv) Prepare primary antibody solution (Androgen receptor Rabbit mAb, Cell Signaling Technology catalog number: 5153; 1:1000 dilution). Discard the solution in the cell plate, add 100μl of primary antibody dilution to each well and incubate overnight at 4 degrees. (v) Discard the primary antibody solution and wash the cell plate with 1× Wash buffer. (vi) Prepare secondary antibody solution (Goat anti Rabbit IgG (H+L) Secondary Antibody, HRP, Thermo catalog number: 31460; 1:5000 dilution), add 100 μl of secondary antibody dilution solution to each well for incubation. (vii) Discard the secondary antibody solution in the cell plate and wash the cell plate with 1× Wash buffer. (viii) Prepare TMB colorimetric solution (BD catalog number: 550534), add 100 μl of colorimetric solution to each well. (ix) Add 50 μl of stop solution (BD catalog number: 550534) to each well. (x) Read the absorbance values at OD 450nm and 570nm using EnVision. (2) (i) Standardize the number of cells in each well. Discard the solution in the cell plate and wash three times with wash buffer. (ii) Prepare Janus dilution solution (1:3 dilution). (iii) Add 50 μl of dilution solution to each well for incubation. (iv) Discard the solution in the plate and wash with deionized water. (v) Prepare 1M hydrochloric acid (concentrated hydrochloric acid is diluted at 1:24) and add 200 μl of the hydrochloric acid dilution to each well to treat the cells. (vi) Read the absorbance value at OD 595nm using the Flex Station. (vii) Based on the obtained reading, calculate the effect of the tested compound on androgen receptor expression.
[0288] The experimental results are shown in Table 1.
[0289] Table 1: Evaluation of the compounds' activity on androgen receptor degradation in LnCaP cells
[0290] Example No. <![CDATA[DC 50 (nM)]]> <![CDATA[D max (%)]]> Example No. <![CDATA[DC 50 (nM)]]> <![CDATA[D max (%)]]> 1 18.9 103 2 7.76 112
[0291] D max:The maximum degradation degree of AR in LnCaP cells. 50 : The concentration of compound required to achieve half of the maximum degradation of AR in LnCaP cells.
[0292] Experimental Example 4: Inhibitory effect of test compounds on LNcap FGC cell proliferation
[0293] The tumor cell line LNcap FGC (ATCC catalog number CRL-1740) was cultured in RPMI 1640 (Gibco catalog number 1 1875-093) and DMEM (Gibco catalog number 1 1965-092) medium containing 10% FBS (Gibco catalog number 10099-141C), respectively.
[0294] The determination method is as follows:
[0295] LNcap FGC cells were seeded in a 384-well plate (PerkinElmer catalog number 6007460) at a cell density of 400 cells / well and a volume of 20 μL / well. After being cultured overnight in a carbon dioxide incubator (Thermo), the prepared compound solutions of different concentrations were added at a volume of 5 μL / well. At the same time, corresponding solvent controls were set up. After continuing to be cultured in the incubator for 6 days, the cell plate and its contents were equilibrated to room temperature, 25 μL of Cell TiterGlor (Promega catalog number G7573) reagent was added to each well, and after oscillation mixing, the plates were incubated in the dark for 10-30 minutes, and the signal values were detected using an Envision microplate reader (PerkinElmer).
[0296] Experimental data processing method:
[0297] The percentage inhibition rate of the compound-treated wells was calculated by the solvent control wells on the plate, and the percentage inhibition rate data corresponding to different concentrations were fitted using GraphPadprism and the IC was calculated using a 4-parameter nonlinear logic formula. 50 value.
[0298] Table 2: Evaluation of the inhibitory activity of compounds on LnCaP cell proliferation
[0299] Example No. <![CDATA[DC 50 (nM)]]> <![CDATA[D max (%)]]> Example No. <![CDATA[DC 50 (nM)]]> <![CDATA[D max (%)]]> 1 69 72 2 3.4 74
[0300] D max : The maximum degree of inhibition of LnCaP cell proliferation. 50 : The concentration of compound required to achieve half of the maximal inhibition of LnCaP cell proliferation.
Claims
1. A compound represented by formula (I), an optical isomer thereof or a pharmaceutically acceptable salt thereof, in, Ring A is selected from 3-9 membered heterocycloalkyl and C 3-9 Cycloalkyl; Ring B is selected from C 6-10 Aryl and 5-10 membered heteroaryl; Ring C is selected from C 6-10 Aryl and 5-10 membered heteroaryl, wherein the C 6-10 Aryl or 5-10 membered heteroaryl is optionally substituted with 1, 2 or 3 R'; R1 is selected from OH, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, -C(=O)-C 1-6 Alkyl, -NHC(=O)-C 1-6 Alkyl and -C(=O)NH-C 1-6 Alkyl, wherein the C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, -C(=O)-C 1-6 Alkyl, -NHC(=O)-C 1-6 Alkyl or -C(=O)NH-C 1-6 The alkyl group is optionally substituted with 1, 2 or 3 R'; R2 is selected from H, halogen, OH, NH2, CN, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino and -C(=O)-C 1-6 Alkyl, wherein the C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino or -C(=O)-C 1-6 The alkyl group is optionally substituted with 1, 2 or 3 R'; R3 is selected from H, halogen, OH, NH2, CN, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, phenyl, naphthyl and 5-10 membered heteroaryl, wherein the C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, phenyl, naphthyl or 5-10 membered heteroaryl is optionally substituted with 1, 2 or 3 R'; R4 and R5 are independently selected from H, NO2, halogen, NH2, CN, C 1-6 Alkyl and C 1-6 Alkoxy, wherein the C 1-6 Alkyl or C 1-6 Alkoxy is optionally substituted with 1, 2 or 3 halogens, OH, NH2; R6 and R7 are independently selected from H, halogen and C 1-6 Alkyl, wherein the C 1-6 The alkyl group is optionally substituted with 1, 2 or 3 R'; Alternatively, R6 and R7 are linked together to form a 3-12 membered heterocycloalkyl or C 3-12 Cycloalkyl, wherein the 3-12 membered heterocycloalkyl or C 3-12 Cycloalkyl is optionally substituted with 1, 2 or 3 Ra; Alternatively, R7 and ring B are connected together to form a 3-12 membered heterocycloalkyl group, C 3-12 Cycloalkyl, C 6-10 aryl or 5-12 membered heteroaryl, wherein the 3-12 membered heterocycloalkyl, C 3-12 Cycloalkyl, C 6-10 Aryl or 5-12 membered heteroaryl is optionally substituted with 1, 2 or 3 Ra; Ra are independently selected from H, halogen and C 1-6 Alkyl, wherein the C 1-6 The alkyl group is optionally substituted with 1, 2 or 3 R'; L1, L2, L3, L4 are independently selected from a single bond, O, S, NH, C(=O), S(=O), S(=O)2, C 1-6 Alkyl, -C 1-6 Alkyl-O-, C 2-3 Alkenyl, C 2-3 Alkynyl, C 3-10 Cycloalkyl, 3-10 membered heterocycloalkyl, phenyl and 5-9 membered heteroaryl, the C 1-6 Alkyl, -C 1-6 Alkyl-O-, C 2-3 Alkenyl, C 2-3 Alkynyl, C 3-10 Cycloalkyl, 3-10 membered heterocycloalkyl, phenyl or 5-9 membered heteroaryl are optionally substituted with 1, 2 or 3 R L replace; R L are independently selected from H, halogen, OH, NH2, CN, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 Alkyl-C(=O)-, C 1-6 Alkoxy, C 1-6 Alkylthio and C 1-6 Alkylamino, the C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 Alkyl-C(=O)-, C 1-6 Alkoxy, C 1-6 Alkylthio or C 1-6 The alkylamino group is optionally substituted with 1, 2 or 3 R'; R' is independently selected from H, halogen, C 1-6 Alkyl, C 1-6 Alkoxy, OH, NH2, CH3, CH2F, CHF2 and CF3; The above-mentioned 3-9-membered heterocycloalkyl, 3-10-membered heterocycloalkyl, 3-12-membered heterocycloalkyl, 5-6-membered heteroaryl, 5-9-membered heteroaryl or 5-10-membered heteroaryl contains 1, 2 or 3 heteroatoms or heteroatom groups independently selected from O, NH, S, C(=O), C(=O)O, S(=O), S(=O)2 and N.
2. The compound according to claim 1, its optical isomer or a pharmaceutically acceptable salt thereof, wherein ring A is selected from 3-6 membered heterocycloalkyl and C 3-6 Cycloalkyl.
3. The compound according to claim 1 or 2, its optical isomer or a pharmaceutically acceptable salt thereof, wherein R1 is selected from OH, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylamino, -C(=O)-C 1-3 Alkyl, -NHC(=O)-C 1-3 Alkyl and -C(=O)NH-C 1-3 Alkyl, wherein the C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylamino, -C(=O)-C 1-3 Alkyl, -NHC(=O)-C 1-3 Alkyl or -C(=O)NH-C 1-3 The alkyl group is optionally substituted with 1, 2 or 3 R'.
4. The compound according to claim 1, its optical isomer or a pharmaceutically acceptable salt thereof, wherein the structural unit Selected from 5. The compound according to claim 1, its optical isomer or a pharmaceutically acceptable salt thereof, wherein the structural unit Selected from 6. The compound according to claim 1, its optical isomer or a pharmaceutically acceptable salt thereof, wherein the structural unit Selected from 7. according to claim 1 described compound, its optical isomer or pharmaceutically acceptable salt thereof, wherein R6 and R7 are linked together to form a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, oxetanyl, tetrahydrofuranyl, tetrahydrothienyl or tetrahydropyranyl, wherein the cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, oxetanyl, tetrahydrofuranyl, tetrahydrothienyl or tetrahydropyranyl are optionally substituted by 1, 2 or 3 Ra.
8. A compound selected from the following formula, an optical isomer thereof or a pharmaceutically acceptable salt thereof:
9. A pharmaceutical composition comprising the compound according to any one of claims 1 to 8, its optical isomer or a pharmaceutically acceptable salt thereof.
10. Use of the compound according to any one of claims 1 to 8, its optical isomer or pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to claim 9 in the preparation of a medicament for preventing and / or treating cancer, prostate cancer, or Kennedy's disease.
